Safety, IL-2 Optimization, and Key Takeaways for Referral

This closing segment focuses on safety and the evolving approach to managing this therapy more thoughtfully. The faculty explain that most toxicity stems from the conditioning chemotherapy and IL-2, and that real-world experience has confirmed no new safety signals. A major theme is the growing recognition that less may be more: the experts discuss how response does not appear driven by the number of IL-2 doses, supporting a more individualized, conservative approach that prioritizes patient safety over reaching a maximum dose. They also touch on ongoing questions around reducing conditioning intensity in select patients. The discussion closes with practical guidance for the broader oncology community, encouraging clinicians to consider cellular therapy candidacy early, ideally when a patient first begins treatment for advanced disease, and to refer in a timely way. The faculty frame this therapy as a preferred option for many patients with checkpoint inhibitor–refractory melanoma.